Key facts
- This page summarizes Kelly Gold's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Jul 2026, 16:20.
Kelly Gold - 01 Jul 2026 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)
- Reporting relationship
- Director
- Issuer ticker
- XFOR
- Reported as of
- 01 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2026, 16:20:10 UTC
- Prior SEC filing
- 03 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Kirske, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kelly Gold filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 01 Jul 2026.
Change
- Previous filing in this sequence was filed on 03 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002033333
Primary reporting owner
Gold Kelly
- Relationship
- Director
- Address
- C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON
- Signature
- /s/ David Kirske, Attorney-In-Fact
- Signature date
- 01 Jul 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XFOR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +110,000
- Change %
- Price
- $0.000000*
- Shares after
- 110,000
- Date
- 01 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 110,000
- Exercise price
- $4.08
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date.